Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab Combinations in Japanese Gastric Cancer
NCT02359058Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2015
- Primary completion
- Jul 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of ramucirumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With One or More Serious Adverse Event(s) Considered Related to Study Drug up to 22 months. Started Feb 2015; status: completed.
02
Drugs
ramucirumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02359058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02359058.